Treatment of acute pulmonary embolism with dabigatran versus warfarin: A pooled analysis of data from RE-COVER and RE-COVER II

Thrombosis and Haemostasis

Volumn 116, Issue 4, 2016, Pages 714-721

  Goldhaber, Samuel Z ^a   Schellong, Sebastian ^f   Kakkar, Ajay ^d   Eriksson, Henry ^c   Feuring, Martin ^e   Kreuzer, Joerg ^e   Fraessdorf, Mandy ^e   Schulman, Sam ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MCMASTER UNIVERSITY   (Canada)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^f ACADEMIC TEACHING HOSPITAL DRESDEN FRIEDRICHSTADT   (Germany)

Author keywords

Dabigatran; Pulmonary embolism; Venous thrombosis; Warfarin

Indexed keywords

DABIGATRAN; WARFARIN; ANTICOAGULANT AGENT;

ADULT; ANTICOAGULATION; ARTICLE; BLEEDING; DEATH; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; THROMBOPHILIA; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; AGED; COMPLICATION; CONTROLLED STUDY; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; VEIN THROMBOSIS;

ADULT; AGED; ANTICOAGULANTS; DABIGATRAN; FEMALE; HUMANS; MALE; MIDDLE AGED; PULMONARY EMBOLISM; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS; WARFARIN;

EID: 84989159396     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH16-04-0271     Document Type: Article

References (8)

1. Office of the Surgeon General (US) and National Heart LaBIU. The Surgeon General’s Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism. Available at: http://www.ncbi.nlm.nih.gov/books/NBK44178/. Accessed November 13, 2015.
2. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran vs warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342–2352.
3. Schulman S, Kakkar AK, Goldhaber SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014; 129: 764–772.
4. Baglin T, Douketis J, Tosetto A, et al. Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient-level meta-analysis. J Thromb Haemost 2010; 8: 2436–2442.
5. White RH. The epidemiology of venous thromboembolism. Circulation 2003; 107: I4-I8.
6. Buller HR, Prins MH, Lensin AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287–1297.
7. Buller HR, Decousus H, Grosso MA, et al. Edoxaban vs warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369: 1406–1415.
8. Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369: 799–808.